These patients had a higher prevalence of concomitant anti-asthmatic medication. chart review, mean follow-up was 20.4??15.7?months. All patients underwent ASA desensitization. Twenty-one patients experienced eventually discontinued therapy after 5.8??4.5?months; 11 for its side effects, 12 for its inefficacy. Twenty patients developed sinunasal complaints soon thereafter. Ten patients were still undergoing Rifapentine (Priftin) desensitization (mean duration … Continue reading These patients had a higher prevalence of concomitant anti-asthmatic medication